{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:50:20Z","timestamp":1791633020488,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaip.2026.09.010","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:57:27Z","timestamp":1790265447000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Respiratory Tract Infections With Asthma Biologics"],"prefix":"10.1016","author":[{"given":"Shane","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Al-Obaydi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-8937","authenticated-orcid":false,"given":"Taha","family":"Al-Shaikhly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.09.010_bib1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1513\/AnnalsATS.201703-259OC","article-title":"The economic burden of asthma in the United States, 2008-2013","volume":"15","author":"Nurmagambetov","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2026.09.010_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/JAA.S272681","article-title":"Medical costs and productivity loss due to mild, moderate, and severe asthma in the United States","volume":"13","author":"Song","year":"2020","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2026.09.010_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.09.010_bib4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.09.010_bib5","article-title":"Efficacy and safety of mepolizumab in the management of severe eosinophilic asthma: a systematic review","volume":"15","author":"Dighriri","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2026.09.010_bib6","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.010_bib7","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.010_bib8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/02770903.2024.2311236","article-title":"Biologics for asthma and risk of pneumonia","volume":"61","author":"Matera","year":"2024","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2026.09.010_bib9","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1038\/s41598-025-91463-5","article-title":"A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database","volume":"15","author":"Song","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2026.09.010_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-024-00653-6","article-title":"Safety of biological therapies for severe asthma: an analysis of suspected adverse reactions reported in the WHO pharmacovigilance database","volume":"38","author":"Cutroneo","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaip.2026.09.010_bib11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-3083.2000.00705.x","article-title":"The role of interleukin-4 in the regulation of sequential isotype switch from immunoglobulin G1 to immunoglobulin E antibody production","volume":"51","author":"Sudowe","year":"2000","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib12","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.74690","article-title":"Macrophage innate training induced by IL-4 and IL-13 activation enhances OXPHOS driven anti-mycobacterial responses","volume":"11","author":"Lundahl","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.jaip.2026.09.010_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","article-title":"Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials","volume":"78","author":"Fleming","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2026.09.010_bib14","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.4049\/jimmunol.172.10.6020","article-title":"The role of IL-5 for mature B-1 cells in homeostatic proliferation, cell survival, and Ig production","volume":"172","author":"Moon","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13223-020-00428-y","article-title":"Local eosinophils are associated with increased IgA subclass levels in the sinonasal mucosa of chronic rhinosinusitis with polyp patients","volume":"16","author":"Aazami","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaf8471","article-title":"A TSLP-complement axis mediates neutrophil killing of methicillin-resistant Staphylococcus aureus","volume":"1","author":"West","year":"2016","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2026.120127","article-title":"Thymic stromal lymphopoietin (TSLP)\u2014pro-inflammatory cytokine and antimicrobial peptide","volume":"1873","author":"D\u00f6hner","year":"2026","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.jaip.2026.09.010_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071949","article-title":"IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance","volume":"8","author":"Lazarski","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2026.09.010_bib19","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.1416922112","article-title":"IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells","volume":"112","author":"Guenova","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2026.09.010_bib20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1183\/09031936.98.12030619","article-title":"Th2 cytokines exert a dominant influence on epithelial cell expression of the major group human rhinovirus receptor, ICAM-1","volume":"12","author":"Bianco","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.09.010_bib21","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3390\/ijms20133222","article-title":"IL-13 impairs tight junctions in airway epithelia","volume":"20","author":"Schmidt","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2026.09.010_bib22","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jaip.2021.12.006","article-title":"Respiratory infections and anti-infective medication use from phase 3 dupilumab respiratory studies","volume":"10","author":"Geng","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.09.010_bib23","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.010_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2026.09.010_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e23725","article-title":"Exploring the risk of infection events in patients with asthma receiving anti-IL-5 monoclonal antibodies: a rapid systematic review and a meta-analysis","volume":"10","author":"Giossi","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jaip.2026.09.010_bib26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2026.09.010_bib27","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.010_bib28","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.09.010_bib29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jaip.2024.10.045","article-title":"A Pharmacovigilance analysis of post-marketing safety of tezepelumab","volume":"13","author":"Li","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.09.010_bib30","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2023","journal-title":"Front Drug Saf Regul"},{"key":"10.1016\/j.jaip.2026.09.010_bib31","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.010_bib32","doi-asserted-by":"crossref","DOI":"10.4161\/tisb.24333","article-title":"Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells","volume":"1","author":"Saatian","year":"2013","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.jaip.2026.09.010_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jaci.2016.03.050","article-title":"Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients","volume":"139","author":"Wawrzyniak","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001339","article-title":"Interleukin-13 promotes susceptibility to chlamydial infection of the respiratory and genital tracts","volume":"7","author":"Asquith","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jaip.2026.09.010_bib35","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1128\/jvi.70.8.5230-5235.1996","article-title":"Interleukin-4 causes delayed virus clearance in influenza virus-infected mice","volume":"70","author":"Moran","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.jaip.2026.09.010_bib36","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jaci.2013.08.039","article-title":"IL-4 blocks TH1-polarizing\/inflammatory cytokine gene expression during monocyte-derived dendritic cell differentiation through histone hypoacetylation","volume":"132","author":"L\u00f3pez-Bravo","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib37","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.anai.2026.01.008","article-title":"Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitis","volume":"136","author":"Cork","year":"2026","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/cei\/uxac038","article-title":"The regulatory role of eosinophils in viral, bacterial, and fungal infections","volume":"209","author":"Gaur","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib39","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.immuni.2014.02.014","article-title":"Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis","volume":"40","author":"Chu","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2026.09.010_bib40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaci.2023.06.005","article-title":"Eosinophils and tissue remodeling: relevance to airway disease","volume":"152","author":"Siddiqui","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.anai.2013.05.010","article-title":"Interaction between allergy and innate immunity: model for eosinophil regulation of epithelial cell interferon expression","volume":"111","author":"Mathur","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib42","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jaip.2020.12.045","article-title":"Eosinophilia in asthma patients is protective against severe COVID-19 illness","volume":"9","author":"Ferastraoaru","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.09.010_bib43","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.jaci.2025.02.025","article-title":"IL-5 enhances human mast cell survival and interferon responses to viral infection","volume":"155","author":"Barra","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib44","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jaip.2025.01.037","article-title":"Anti-IL-5 treatment reduces infection-related adverse events: a meta-analysis of phase 3 clinical trials","volume":"13","author":"Lustberg","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.09.010_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaci.2012.05.023","article-title":"Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children","volume":"130","author":"Durrani","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib46","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201701-0120OC","article-title":"Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma","volume":"196","author":"Esquivel","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.09.010_bib47","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002024","article-title":"Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study","volume":"13","author":"Fardet","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.jaip.2026.09.010_bib49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1164\/rccm.202402-0368OC","article-title":"Association of dose of inhaled corticosteroids and frequency of adverse events","volume":"211","author":"Bloom","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.09.010_bib50","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.chest.2020.10.050","article-title":"Adherence to asthma biologics: implications for patient selection, step therapy, and outcomes","volume":"159","author":"Maddux","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.09.010_bib51","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.anai.2023.07.017","article-title":"Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results","volume":"131","author":"Ledford","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib52","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.anai.2021.04.026","article-title":"Persistence of asthma biologic use in a US claims database","volume":"127","author":"Maddux","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib53","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2021.06.006","article-title":"COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: nationwide real-world evidence","volume":"148","author":"Adir","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.010_bib54","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.jaip.2022.05.041","article-title":"SARS-Cov-2 infection in severe asthma patients treated with biologics","volume":"10","author":"Papaioannou","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.09.010_bib55","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01076-2021","article-title":"Biologics may have a beneficial effect in asthma patients with COVID-19","volume":"58","author":"Izquierdo","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.09.010_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae102","article-title":"COVID-19 immunologic antiviral therapy with omalizumab (CIAO)\u2014a randomized controlled clinical trial","volume":"11","author":"Le","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jaip.2026.09.010_bib57","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1164\/rccm.202111-2496LE","article-title":"Reduced COVID-19 vaccine response in patients treated with biologic therapies for asthma","volume":"205","author":"Runnstrom","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.09.010_bib58","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.202203-0599LE","article-title":"SARS-CoV-2 mRNA vaccine antibody response in patients with asthma receiving biologic therapy: a real-world analysis","volume":"206","author":"Liao","year":"2022","journal-title":"Am J Respir Crit Care Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826007853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826007853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:34:12Z","timestamp":1791632052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219826007853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"alternative-id":["S2213219826007853"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.09.010","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Respiratory Tract Infections With Asthma Biologics","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}